WO2001021162A2 - Treating allergic and inflammatory conditions using desloratadine - Google Patents
Treating allergic and inflammatory conditions using desloratadine Download PDFInfo
- Publication number
- WO2001021162A2 WO2001021162A2 PCT/US2000/025609 US0025609W WO0121162A2 WO 2001021162 A2 WO2001021162 A2 WO 2001021162A2 US 0025609 W US0025609 W US 0025609W WO 0121162 A2 WO0121162 A2 WO 0121162A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- desloratadine
- allergic
- work
- person
- related performance
- Prior art date
Links
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 title claims abstract description 54
- 229960001271 desloratadine Drugs 0.000 title claims abstract description 54
- 230000000172 allergic effect Effects 0.000 title claims abstract description 27
- 208000010668 atopic eczema Diseases 0.000 title claims abstract description 26
- 230000004968 inflammatory condition Effects 0.000 title claims abstract description 24
- 201000010105 allergic rhinitis Diseases 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- 208000024780 Urticaria Diseases 0.000 claims abstract description 7
- 201000008937 atopic dermatitis Diseases 0.000 claims abstract description 7
- 206010012438 Dermatitis atopic Diseases 0.000 claims abstract description 6
- 206010039094 Rhinitis perennial Diseases 0.000 claims abstract description 4
- 208000006673 asthma Diseases 0.000 claims abstract description 4
- 208000022719 perennial allergic rhinitis Diseases 0.000 claims abstract description 4
- 201000009961 allergic asthma Diseases 0.000 claims abstract description 3
- 208000036284 Rhinitis seasonal Diseases 0.000 claims description 12
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 11
- 208000017022 seasonal allergic rhinitis Diseases 0.000 claims description 11
- 230000001932 seasonal effect Effects 0.000 claims description 2
- 206010039085 Rhinitis allergic Diseases 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 description 20
- 238000000034 method Methods 0.000 description 16
- 230000000694 effects Effects 0.000 description 12
- 229960000520 diphenhydramine Drugs 0.000 description 9
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 9
- 239000009342 ragweed pollen Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 239000000739 antihistaminic agent Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000002483 medication Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 5
- 230000001387 anti-histamine Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 230000006735 deficit Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000000938 histamine H1 antagonist Substances 0.000 description 4
- 229960003088 loratadine Drugs 0.000 description 4
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000001624 sedative effect Effects 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000000850 decongestant Substances 0.000 description 3
- 229940029077 desloratadine 5 mg Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 244000036975 Ambrosia artemisiifolia Species 0.000 description 2
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- -1 HNO3 Chemical class 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010028735 Nasal congestion Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 208000036071 Rhinorrhea Diseases 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 206010041232 sneezing Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- YAWVFJYLSIMLAY-UHFFFAOYSA-N 2-acetyloxybenzoic acid;2-[4-(2-methylpropyl)phenyl]propanoic acid Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 YAWVFJYLSIMLAY-UHFFFAOYSA-N 0.000 description 1
- 206010053779 Allergic cough Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 206010052140 Eye pruritus Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000000543 Histamine Receptors Human genes 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010068773 Mechanical urticaria Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010052437 Nasal discomfort Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000013567 aeroallergen Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 208000029618 autoimmune pulmonary alveolar proteinosis Diseases 0.000 description 1
- 230000037424 autonomic function Effects 0.000 description 1
- 229940088007 benadryl Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical class C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000000409 dermatographia Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 208000020157 familial dermatographia Diseases 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000010659 intrinsic asthma Diseases 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000037916 non-allergic rhinitis Diseases 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 229960003908 pseudoephedrine Drugs 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000010332 selective attention Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Definitions
- compositions of desloratadine be adapted for any mode of administration e.g., for oral, parenteral, e.g., subcutaneous ('SC"), intramuscular (“IM”), intravenous (“IV”) and intraperitoneal (“IP”), topical or vaginal administration or by inhalation (orally or intranasally).
- 'SC subcutaneous
- IM intramuscular
- IV intravenous
- IP intraperitoneal
- desloratadine is administered orally.
- the pharmaceutical composition is in a unit dosage form.
- the preparation is subdivided into suitably sized unit doses containing appropriate quantities of desloratadine and other, if any active component, e.g., effective amounts to achieve the desired purpose.
Abstract
The use of desloratadine for the preparation of a medicament for substantially returning work-related performance and/or workplace productivity of a person suffering from an allergic and/or inflammatory condition of the skin airway passages, e.g., season allergic rhinitis, perennial allergic rhinitis, atopic dermatitis, urticaria or allergic asthma to the person's baseline work-related performance and baseline workplace productivity.
Description
TREATING ALLERGIC AND INFLAMMATORY CONDITIONS
BACKGROUND OF THE INVENTION
This invention relates to the use of desloratadine for the preparation of a medicament for substantially returning work-related performance and/or workplace productivity of a patient suffering from an allergic and/or inflammatory condition to the person's baseline work-related performance and baseline workplace productivity.
The symptoms and side effects of an allergic and/or inflammatory condition of the skin or upper and lower airway passages such as seasonal allergic rhinitis ("SAR") include itchy, watery eyes, sneezing, runny nose, nasal congestion, urticaria, sommolence and general malaise. The pharmacologic effects of treating allergic and/or inflammatory condition such as SAR with sedating antihistamines include sommolence, blurred vision, dry mouth and individual performance impairment at home, in school and at work as well as impairment of workplace productivity. SAR affects up to 45 million people in the United States and many more millions worldwide. Cockurn, lain M, et al., in Business & Health. March 1999, pages 49-
50 and in J Occup Eniviron Med.. November 1999, Vol. 41(11 ), pages 948-953 disclose treating allergic reactions with sedating antihistamines, alone or in combination with decongestants, leads to impaired individual performance and decreased workplace productivity of workers compared to treatment with non- sedating antihistamines.
In view of the high prevalence of SAR, even relatively small effects on individual performance will have a significant impact on work-related performance and workplace productivity in the worldwide population, Thus, there is a need for a clinically more effective therapy for treating/preventing an allergic and or inflammatory condition of the skin and upper or lower airway passages in workers while simultaneously enhancing their work-related performance as well as their workplace productivity.
SUMMARY OF THE INVENTION
The present invention provides a method of substantially returning the work-related performance of a person suffering from an allergic and/or inflammatory condition of the skin or airway passages to the person's baseline work-related performance which comprises administering an amount of desloratadine to said person effective for such returning.
The present invention provides a method of returning workplace productivity of a person suffering from an allergic and/or inflammatory condition of the skin or airway passages to the person's baseline workplace productivity which comprises administering an effective amount of desloratadine to said person effective for such returning.
In a preferred embodiment, the present invention provides a method of substantially returning work-related performance of a person suffering from seasonal allergic rhinitis to the person's baseline work-related performance which comprises administering an amount of desloratadine to such person effective for such returning.
In a preferred embodiment, the present invention provides a method of substantially returning workplace productivity of a person suffering from seasonal allergic rhinitis to the person's baseline workplace productivity which comprises administering an amount of desloratadine to said person effective for such returning.
In another preferred embodiment, the present invention provides a method of enhancing work-related performance of a patient suffering from atopic dermatitis or urticaria which comprises administering an amount of desloratadine effective for such enhancing. In another preferred embodiment, the present invention provides a method of substantially returning workplace productivity of a person suffering from atopic dermatitis or urticaria to the person's baseline work-related performance to the person's baseline work-related performance which comprises administering an amount of desloratadine effective for such returning. In another preferred embodiment, the present invention provides a method of returning performance of a person suffering from atopic dermatitis or urticaria to
the person's baseline workplace productivity which comprises administering an amount of desloratadine to said person effective for such returning.
In another preferred embodiment, the present invention provides a method of substantially returning workplace productivity of a person suffering from an allergic and/ or inflammatory condition of the skin or passages to the person's baseline workplace productivity by administering an initial amount of desloratadine to said person effective for such returning.
In another preferred embodiment, the present invention provides a method of substantially returning performance of a person suffering from an allergic and/ or inflammatory condition of the skin or airway passages to the person's baseline workplace productivity by administering an initial amount of desloratadine to said person effective for such returning.
The invention also contemplates pharmaceutical compositions for substantially returning work-related performance and/or workplace productivity of a person suffering from an allergic and/or inflammatory condition of the skin or airway passage to the person's baseline work-related performance and/or workplace performance comprising an amount of desloratadine effective for such returning.
DETAILED DESCRIPTION OF THE INVENTION Persons afflicted with the symptoms and side effects of an allergic and/or inflammatory condition of the skin and upper or lower airway passages -such as seasonal allergic rhinitis- who are treated with an initial effective amount of desloratadine exhibit a significantly higher work-related performance and a significantly higher workplace productivity in a controlled clinical setting compared to untreated persons as well as with persons treated with an initial standard dose of the sedating antihistamine, diphenhydramine.
The phrase "the person's baseline work-related performance" as used herein means the person's work-related performance at a time prior to the person's exhibiting signs and/or symptoms of allergic and/or inflammatory conditions of the skin or airway passages as measured by art-recognized methods hereinafter described.
The phrase "the person's baseline workplace productivity" as used herein means the person's baseline workplace productivity as used herein means the person's performance at a time prior to the person's exhibiting the signs and/or symptoms of allergic and/or inflammatory conditions of the skin or airway passages as measured by art-recognized methods hereinafter described. The phrase "substantially returning" as used herein in reference to a person's baseline work-related performance or baseline workplace productivity means returning to within about 5-10%, preferably within about 5% and more preferably within about 1-2% of the baseline values. The phrase "allergic and/ or inflammatory conditions of the skin or airway passages" as used herein means those allergic and/or inflammatory conditions and symptoms found on the skin and in the airway passages from the nose to the lungs. Typical allergic and/or inflammatory conditions of the skin and upper and lower airway passages include seasonal and perennial allergic rhinitis, non- allergic rhinitis, asthma including allergic and non-allergic asthma, sinusitis, colds (in combination with a NSAID, e.g., aspirin ibuprofen or APAP) and/or a decongestant e.g. pseudoephedrine), dermatitis, especially allergic and atopic dermatitis, and urticaria and symptomatic dermographism as well as retinophathy, and small vessel diseases, associated with diabetes mellitus. The amount of desloratadine effective for treating or preventing allergic and/or inflammatory conditions of the skin and upper and lower airway passages will vary with the age, sex, body weight and severity of the allergic and inflammatory condition of the patient. Typically, the amount of desloratadine effective for treating or preventing such allergic and inflammatory conditions is in the range of about 2.5 mg/day to about 45 mg/day, preferably about 2.5 mg/day to about 20 mg/day, or about 4.0 mg/day to about 15 mg/day, or about 5.0 mg/day to about 10 mg/day, more preferably about 5.0 mg/day to about 7.5 mg/day, and most preferably about 5.0 mg/day in single or divided doses, e.g. two 2.5 mg doses, or about 5.0 mg/day in a single dose. Desloratadine is a non-sedating long acting histamine antagonist with potent selective peripheral H1 -receptor antagonist activity. Following oral administration, loratadine is rapidly metabolized to descarboethoxyloratadine or
desloratadine, a pharmacologically active metabolite. In vitro and in vivo animal pharmacology studies have been conducted to assess various pharmacodynamic effects of desloratadine and loratadine. In assessing antihistamine activity in mice (comparison of ED50 value), desloratadine was relatively free of producing alterations in behavior alterations in behavior, neurologic or autonomic function. The potential for desloratadine or loratadine to occupy brain H1 -receptors was assessed in guinea pigs following i.p. administration and results suggest poor access to central histamine receptors for desloratadine or loratadine.
In vivo studies also suggest that an inhibitory effect of desloratadine on allergic bronchospasm and cough can also be expected.
The clinical efficacy and safety of desloratadine has been documented in over 3,200 seasonal allergic rhinitis patients in 4 double-blind, randomized clinical trials. The results of these chemical studies demonstrated the efficacy of desloratadine in the treatment of adult and adolescent patients with seasonal rhinitis.
Desloratadine is particularly useful for the treatment and prevention of the nasal (stuffiness/congestion, rhinorrhea, nasal itching, sneezing) and non-nasal (itchy/burning eyes, tearing/watery eyes, redness of the eyes, itching of the ears/palate) symptoms of seasonal allergic rhinitis, including nasal congestion, in patients in need of such treating and/ or preventing. Desloratadine may be used alone, or in combination with a decongestant, e.g., pseudeoephridine and/or an analgesic, e.g., a NSAID such as acetominophen or ibuprofen.
STUDY DESIGNS AND CONCEPTS A series of randomized, double-blinded(treatment), placebo-controlled studies have been designed to quantify the impact of seasonal allergic rhinitis ("SAR") and SAR treatments on work-related performance and workplace productivity of subjects as measured by art-recognized selected areas of performance and workplace productivity. In one series of studies, the effects of SAR (burden of disease) in subjects will be quantified by comparing the work- related performance levels in asymptomatic SAR subjects to the work-related subjects performance levels in symptomatic SAR subjects. In another series of
studies, the differential impact following two different treatments for SAR on work- related performance of subjects will be quantified: the effects of desloratadine 5 mg tablets will be compared to diphenhydramine 50 mg (and placebo of each drug) among subjects with symptomatic SAR during exposure of the subjects to ragweed pollen. A consistent level of ragweed pollen exposure will be assured by conducting these studies in an environmental exposure unit (EEU). The baseline work-related performance and baseline workplace productivity of each subject will be measured at day 0 prior to exposure to ragweed pollen in the EEU. WORK-RELATED PERFORMANCE TESTS The work-related performance abilities of the subjects to be examined in one study series were selected based on the consensus of an expert panel consisting of neuropsychologists, industrial psychologists, and allergists. These work-related performance abilities cover the domains thought to be most affected by the symptoms of SAR and/or by sedation caused by SAR treatments. In addition, the expert panel prioritized those performance domains that are most closely related to abilities associated with safety and productivity. The work- related performance abilities were then mapped by the expert panel to neuropyschological performance tests. PRIMARY ENDPOINT: The effects of SAR(also called the burden of disease) will be measured by measuring the selective attention in asymptomatic versus symtomatic subjects and in symptomatic subjects treated with desloratadine 5 mg tablets versus symptomatic subjects treated diphenhydramine 50 mg.
1. Impact of Treatment (Desloratadine vs. Diphenhydramine) will be determined by measuring the perceptual speed in asymptomatic versus symtomatic subjects and in symptomatic subjects treated with desloratadine 5 mg tablets versus symptomatic subjects treated diphenhydramine 50 mg.
2. Burden of Disease will be measured in asymptomatic vs. symptomatic subjects; and in symptomatic subjects vs. those treated with Desloratadine by measuring the information ordering as follows:
3. OTHER ENDPOINTS:
Additional measures of some of the performance domains will also be included as secondary endpoints. These include, but are not limited to, problem sensitivity, memorization, number facility, time sharing, and response orientation, and rate control.
INCLUSION AND EXCLUSION CRITERIA Finally, standard inclusion and exclusion criteria will be used to assure that other factors, such as nicotine and/or alcohol use or sleep disturbances, are not contributing to any observed effect.
ENVIRONMENTAL EXPOSURE UNIT (EEU) The EEU is a scientifically recognized pollen exposure system that has been used to evaluate the efficacy of anti-allergic medications, including determinations of the "onset of action" of these medications to relieve the signs and symptoms of pollen-induced allergic rhinitis. The controlled exposure to an aeroallergen, usually short ragweed pollen, has eliminated variables associated with other methods of clinical evaluation of these medications. The clinical relevance of the results of this test system have been validated by comparison of
the results of clinical trails in this unit with those of other modes of allergen challenge, in particular exposure of allergic subjects to natural environmental increases in pollen levels.
Prior to those study days when the subjects are to be symptomatic and will undergo work-related performance and work-place productivity testing, they will be exposed during two to six priming sessions of 3 hours each to controlled pollen levels (3500 ± 500 grains/m3) in the EEU. Subjects will record symptom severity every 30 minutes until the symptom severity criteria for enrollment in the study are met or the 3 hours have lapsed following which they will be transferred to a pollen- free room for up to one hour of observation. Subjects whose symptoms are so severe that they cannot remain in the EEU for at least 3 hours are moved to a pollen-free room and discharged from the study. To qualify for enrollment the subjects are required to achieve a total SAR symptom severity score of >10 made up of a nasal symptom score of >6 and of >4 for the non-nasal symptoms. On leaving the EEU those subjects who meet the severity scores inclusion criteria will be assigned to computer-generated randomization.
On the Baseline (symptomatic) and treatment-study days the enrolled subjects will report to the EEU at 7:30 AM. They will complete the daily baseline pre-exposure evaluation of their SAR symptom severity at 8:00 AM, following which they will begin exposure to ragweed pollen (3500±500 grain/m3) for 8 hours, i.e., from 8:00 AM to 4:00 PM. Promptly following symptom severity ratings at 9:30 AM, the subjects will be evaluated for qualification for dosing and continuation in the study. Immediately after completing the 10:00 AM dairy card, all subjects will take their medications with a glass (180 ml_) of water. The work-related performance and work-place productivity testing will begin approximately 1 ΛA hours after the initial dosing and will continue until approximately 2 hours after the initial dosing. This timing will allow for testing to be completed during the time that the two drugs are expected to show efficacy.
WORK-PLACE PRODUCTIVITY TESTS The work-place productivity tests selected will be based on their sensitivity to the effects of sedation and seasonal allergic rhinitis symptoms, and
their relevance to the skills required for word processing. The same subject inclusion/exclusion criteria used for the work-related performance studies will be used. A consistent level of ragweed pollen exposure will be assured by conducting these studies in the above-described environmental exposure unit (EEU).
PRIMARY STUDY OBJECTIVE:
To show that work-place productivity is higher when subjects with symptomatic SAR are treated with desloratadine, 5 mg tablets antihistamine, than when subjects are treated with diphenhydramine 50 mg, a sedating antihistamine after exposure of both sets of subjects to ragweed pollen in an above-described EEU.
SECONDARY STUDY OBJECTIVES:
1. To show that work-related performance and workplace productivity are higher when subjects with symptomatic SAR are treated with desloratadine than when they are not treated; and 2. To show that SAR negatively impacts workplace productivity.
RESEARCH BACKGROUND FOR THE STUDIES The hypotheses that relate to the objectives for these studies are based on the documented findings that dosing with diphenhydramine causes somnolence and impairment of cognitive and psychomotor functions and vigilance and intuitive projections, and that the signs and symptoms of SAR adversely affect those same functions. SAR may exert its impairing effects not only by affecting visual and auditory responses and upper airway breathing capacity but also by a sense of general malaise and discomfort. These impairments of work-related performance should result in diminished workplace productivity. The study subjects, who will have a history of ragweed pollen associated
SAR and a documented positive skin test to short ragweed pollen, will be evaluated while asymptomatic and symptomatic to establish baseline work-related
performance and workplace productivity data to meet the study objectives. Because these subjects will be evaluated for the effects of their SAR signs and symptoms and of the two study medications on individual performance and workplace productivity, they will need to meet at least minimal requirements for typing/word processing skills.
Both medications (desloratadine and diphenhydramine) are expected to relieve the signs and symptoms of SAR during the course of the treatment study day, beginning as soon as one-and-one half-hours after dosing and continuing during the testing periods. GENERAL EXPERIMENTAL
U.S. Patent No. 4,659,716 discloses desloratadine as a non-sedating antihistamine as well as methods of making desloratadine, pharmaceutical compositions containing it and methods of using desloratadine and pharmaceutical compositions containing it to treat allergic reaction in mammals. U.S. Patent No. 5,595,997 discloses pharmaceutical compositions containing desloratadine and methods of using desloratadine for treating allergic rhinitis.
Desloratadine is available from Schering Corporation, Kenilworth, N . Diphenhydramine is available under the BENADRYL trademark on a non- prescription basis.
The pharmaceutical compositions of desloratadine be adapted for any mode of administration e.g., for oral, parenteral, e.g., subcutaneous ('SC"), intramuscular ("IM"), intravenous ("IV") and intraperitoneal ("IP"), topical or vaginal administration or by inhalation (orally or intranasally). Preferably desloratadine is administered orally.
Such compositions may be formulated by combining desloratadine or an equivalent amount of a pharmaceutically acceptable salt thereof with a suitable, inert, pharmaceutically acceptable carrier or diluent which may be either solid or liquid. Desloratadine may be converted into the pharmaceutically acceptable acid addition salts by admixing it with an equivalent amount of a pharmaceutically acceptable acid. Typically suitable pharmaceutically acceptable acids include the mineral acids, e.g., HNO3, H2SO , H3PO | HCI, HBr, organic acids, including, but
not limited to, acetic, trifluoroacetic, propionic, lactic, maleic, succinic, tartaric, glucuronic and citric acids as well as alkyl or arylsulfonic acids, such as p- toluenesulfonic acid, 2-naphthalenesulfonic acid, or methanesulfonic acid. The preferred pharmaceutically acceptable salts are trifluoroacetate, tosylate, mesylate, and chloride. Desloratadine is more stable as the free base than as an acid addition salt and the use of the desloratadine free base in pharmaceutical compositions of the present invention is more preferred.
Solid form compositions include powders, tablets, dispersible granules, capsules, cachets and suppositories. The powders and tablets may be comprised of from about 5 to about 95 percent active ingredient. Suitable solid carriers are known in the art, e.g. magnesium carbonate, magnesium stearate, talc, sugar or lactose. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration. Examples of pharmaceutically acceptable carriers and methods of manufacture for various compositions may be found in A. Gennaro (ed.), Remington's Pharmaceutical Sciences, 18th Edition, (1990), Mack Publishing Co., Easton, Pennsylvania.
Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection. Solid form preparations may be converted into liquid preparations shortly before use for either oral or administration. Parenteral forms to be injected intravenously, intramuscularly or subcutaneously are usually in the form of sterile solutions and may contain tonicity agents (salts or glucose), and buffers. Opacifiers may be included in oral solutions, suspensions and emulsions. Liquid form preparations may also include solutions for intranasal administration. Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas, e.g., nitrogen.
Also included are solid form preparations that are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions and emulsions.
Desloratadine may also be deliverable transdermally. The transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.
Preferably, the pharmaceutical composition is in a unit dosage form. In such form, the preparation is subdivided into suitably sized unit doses containing appropriate quantities of desloratadine and other, if any active component, e.g., effective amounts to achieve the desired purpose.
Claims
(1 ) The use of desloratadine for the preparation of a medicament for substantially returning work-related performance of a person suffering from an allergic and/or inflammatory condition of the skin or airway passages to the person's baseline work-related performance.
(2) The use of desloratadine for the preparation of a medicament for substantially returning workplace productivity of a person suffering from an allergic and/or inflammatory condition of the skin or airway passages to the person's baseline workplace productivity.
(3) The use of desloratadine for the preparation of a medicament for substantially returning work-related performance of a person suffering from seasonal or perennial allergic rhinitis to the person's baseline work-related performance.
(4) The use of any preceding claim wherein the amount of desloratadine is about 2.5 mg/day to about 45 mg/day.
(5) The use of any preceding claim wherein the amount of desloratadine is about 5 mg/day to about 15 mg/day.
(6) The use of any preceding claim wherein the amount of desloratadine is about 5 mg/day to about 10 mg/day.
(7) The use of any preceding claim wherein the amount of desloratadine is about 5 mg/day. (8) The use of any preceding claim wherein the allergic and/or inflammatory condition of the skin or airway passages is seasonal allergic rhinitis, perennial allergic rhinitis, atopic dermatitis, urticaria or allergic asthma.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU75897/00A AU7589700A (en) | 1999-09-22 | 2000-09-19 | Treating allergic and inflammatory conditions |
| CA002383214A CA2383214A1 (en) | 1999-09-22 | 2000-09-19 | Treating allergic and inflammatory conditions |
| JP2001524588A JP2003509459A (en) | 1999-09-22 | 2000-09-19 | Treatment of allergic and inflammatory conditions |
| EP00965127A EP1214071A2 (en) | 1999-09-22 | 2000-09-19 | Treating allergic and inflammatory conditions using desloratadine |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40059999A | 1999-09-22 | 1999-09-22 | |
| US09/400,599 | 1999-09-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2001021162A2 true WO2001021162A2 (en) | 2001-03-29 |
| WO2001021162A3 WO2001021162A3 (en) | 2002-03-07 |
Family
ID=23584252
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2000/025609 WO2001021162A2 (en) | 1999-09-22 | 2000-09-19 | Treating allergic and inflammatory conditions using desloratadine |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1214071A2 (en) |
| JP (1) | JP2003509459A (en) |
| AR (1) | AR025724A1 (en) |
| AU (1) | AU7589700A (en) |
| CA (1) | CA2383214A1 (en) |
| PE (1) | PE20010752A1 (en) |
| WO (1) | WO2001021162A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001056574A1 (en) * | 2000-02-03 | 2001-08-09 | Schering Corporation | Use of desloratadine for treating allergic and inflammatory conditions |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4659716A (en) * | 1984-02-15 | 1987-04-21 | Schering Corporation | Antihistaminic 8-(halo)-substituted 6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridines |
| US5595997A (en) * | 1994-12-30 | 1997-01-21 | Sepracor Inc. | Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine |
| WO1998006394A1 (en) * | 1996-08-16 | 1998-02-19 | Schering Corporation | Treatment of upper airway allergic responses with a combination of histamine receptor antagonists |
| WO1998034614A1 (en) * | 1997-02-07 | 1998-08-13 | Sepracor, Inc. | Lactose-free, non-hygroscopic and anhydrous pharmaceutical compositions of descarboethoxyloratadine |
| WO1998048803A1 (en) * | 1997-04-25 | 1998-11-05 | Schering-Plough Kabushiki Kaisha | Eyedrops |
| US5900421A (en) * | 1997-02-11 | 1999-05-04 | Sepracor Inc. | Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine |
-
2000
- 2000-09-19 EP EP00965127A patent/EP1214071A2/en not_active Withdrawn
- 2000-09-19 AU AU75897/00A patent/AU7589700A/en not_active Abandoned
- 2000-09-19 JP JP2001524588A patent/JP2003509459A/en not_active Withdrawn
- 2000-09-19 WO PCT/US2000/025609 patent/WO2001021162A2/en not_active Application Discontinuation
- 2000-09-19 CA CA002383214A patent/CA2383214A1/en not_active Abandoned
- 2000-09-19 PE PE2000000969A patent/PE20010752A1/en not_active Application Discontinuation
- 2000-09-20 AR ARP000104928A patent/AR025724A1/en unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4659716A (en) * | 1984-02-15 | 1987-04-21 | Schering Corporation | Antihistaminic 8-(halo)-substituted 6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridines |
| US5595997A (en) * | 1994-12-30 | 1997-01-21 | Sepracor Inc. | Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine |
| WO1998006394A1 (en) * | 1996-08-16 | 1998-02-19 | Schering Corporation | Treatment of upper airway allergic responses with a combination of histamine receptor antagonists |
| WO1998034614A1 (en) * | 1997-02-07 | 1998-08-13 | Sepracor, Inc. | Lactose-free, non-hygroscopic and anhydrous pharmaceutical compositions of descarboethoxyloratadine |
| US5900421A (en) * | 1997-02-11 | 1999-05-04 | Sepracor Inc. | Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine |
| WO1998048803A1 (en) * | 1997-04-25 | 1998-11-05 | Schering-Plough Kabushiki Kaisha | Eyedrops |
Non-Patent Citations (3)
| Title |
|---|
| GENOVESE: "loratadine and desethoxycarbonyl loratadine..." CLINICAL AND EXPERIMENTAL ALLERGY, vol. 27, no. 5, 1997, pages 559-567, XP000998792 * |
| HANDLEY DEAN A ET AL: "Methods for treating dermatitis using descarboethoxyloratadine." 25 April 2000 (2000-04-25) , OFFICIAL GAZETTE OF THE UNITED STATES PATENT AND TRADEMARK OFFICE, VOL. 1233, NR. 4, PAGE(S) NO PAGINATION , APR. 25, 2000 XP000997862 ISSN: 0098-1133 the whole document * |
| MOLET, S. ET AL: "Inhibitory activity of loratadine and descarboxyethoxyloratadine on histamine-induced activation of endothelial cells" CLIN. EXP. ALLERGY ( 1997 ), 27(10), 1167-1174 , XP000997866 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001056574A1 (en) * | 2000-02-03 | 2001-08-09 | Schering Corporation | Use of desloratadine for treating allergic and inflammatory conditions |
| US7405223B2 (en) | 2000-02-03 | 2008-07-29 | Schering Corporation | Treating allergic and inflammatory conditions |
| US7902208B2 (en) | 2000-02-03 | 2011-03-08 | Schering Corporation | Treating allergic and inflammatory conditions |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001021162A3 (en) | 2002-03-07 |
| AU7589700A (en) | 2001-04-24 |
| CA2383214A1 (en) | 2001-03-29 |
| EP1214071A2 (en) | 2002-06-19 |
| JP2003509459A (en) | 2003-03-11 |
| AR025724A1 (en) | 2002-12-11 |
| PE20010752A1 (en) | 2001-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Grant et al. | Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial | |
| US20060276495A1 (en) | Treatment methods of nasal congestion and nasal obstruction | |
| Day et al. | Onset of action, efficacy, and safety of a single dose of fexofenadine hydrochloride for ragweed allergy using an environmental exposure unit | |
| US7902208B2 (en) | Treating allergic and inflammatory conditions | |
| Aaronson | Evaluation of cetirizine in patients with allergic rhinitis and perennial asthma | |
| JP2012502103A (en) | Method of using a sustained release aminopyridine composition | |
| Prenner et al. | Efficacy and tolerability of loratadine versus fexofenadine in the treatment of seasonal allergic rhinitis: a double-blind comparison with crossover treatment of nonresponders | |
| Day | Pros and cons of the use of antihistamines in managing allergic rhinitis | |
| CA2398261A1 (en) | Treating allergic and inflammatory conditions | |
| KR20140084120A (en) | Methods for treating a stroke-related sensorimotor impairment using aminopyridines | |
| Kaiser | H1-receptor antagonist treatment of seasonal allergic rhinitis | |
| EP1214071A2 (en) | Treating allergic and inflammatory conditions using desloratadine | |
| Corren et al. | Onset and duration of action of levocabastine nasal spray in atopic patients under nasal challenge conditions | |
| US20050203117A1 (en) | Treating allergic and inflammatory conditions | |
| Ngamphaiboon et al. | The efficacy and safety of 30 mg fexofenadine HCl bid in pediatric patients with allergic rhinitis | |
| Hampel Jr et al. | Efficacy and safety of levocabastine nasal spray for seasonal allergic rhinitis | |
| Knight et al. | Clinical evaluation of the efficacy and safety of noberastine, a new H1 antagonist, in seasonal allergic rhinitis: A placebo-controlled, dose-response study | |
| White et al. | Comparative effects of fexofenadine and montelukast on allergen-induced wheal and flare | |
| EP1401444A1 (en) | Antihistamines for the treatment of nasal congestion and nasal obstruction | |
| Jones et al. | Use of olopatadine ophthalmic solution and reactivity of histamine skin testing. | |
| DE BENEDICTIS et al. | Efficacy and safety of cetirizine and oxatomide in young children with perennial allergic rhinitis: a 10-day, multicenter, double-blinded, randomized, parallel-group study | |
| US20040138247A1 (en) | Use of desloratadine for treating allergic and inflammatory conditions | |
| AU2002315357A1 (en) | Antihistamines for the treatment of nasal congestion and nasal obstruction | |
| Tarasido | Azatadine maleate/pseudoephedrine sulfate repetabs versus placebo in the treatment of severe seasonal allergic rhinitis | |
| WO2001045688A2 (en) | Use od desloratadine for treating allergic and inflammatory conditions in pediatric patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CZ DE DK DM DZ EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX MZ NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA US UZ VN YU ZA |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2383214 Country of ref document: CA |
|
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CZ DE DK DM DZ EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX MZ NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA US UZ VN YU ZA |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| ENP | Entry into the national phase in: |
Ref country code: JP Ref document number: 2001 524588 Kind code of ref document: A Format of ref document f/p: F |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 10088629 Country of ref document: US |
|
| WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/003023 Country of ref document: MX |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2000965127 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 2000965127 Country of ref document: EP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 2000965127 Country of ref document: EP |